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A B S T R A C T
Human colorectal cancer is the third most common cancer around the world. Colorectal cancer has various risk
factors, but current works have bolded a significant activity for the microbiota of the human colon in the
development of this disease. Bacterial biofilm has been mediated to non-malignant pathologies like in-
flammatory bowel disease but has not been fully documented in the setting of colorectal cancer. The in-
vestigation has currently found that bacterial biofilm is mediated to colon cancer in the human and linked to the
location of human cancer, with almost all right-sided adenomas of colon cancers possessing bacterial biofilm,
whilst left-sided cancer is rarely biofilm positive. The profound comprehension of the changes in colorectal
cancer can provide interesting novel concepts for anticancer treatments. In this review, we will summarize and
examine the new knowledge about the links between colorectal cancer and bacterial biofilm.
1. Introduction
Colorectal cancer is the third common cancer in males and the
second common cancer in females, and it was 1.8 million new instances
in the current year in the world [1–3]. It is the second leading cause of
cancer deaths worldwide [4]. Approximately 55% of the colorectal
cancer cases happen in developed countries [5]. In the industrialized
countries, the lifetime risk of developing colorectal cancer is up to 5%,
and the lifetime risk of developing an adenoma, a non-cancerous colon
tumor that could make expanse into colorectal cancer, is 20% [5].
Despite tremendous development in the treatment of diseases, color-
ectal cancer is still a serious health problem in developed countries [6].
Various risk factors proposed for colorectal cancer, but currently have
bolded a significant activity for the colon microbiota in the develop-
ment of this disease [5,7–11]. Bacterial biofilm has been associated
with non-malignant pathologies like Inflammatory Bowel Disease (IBD)
but has not been fully demonstrated in the setting of colon cancer [12].
The investigation has found that bacterial biofilm is mediated to human
colon cancer and linked to the location of cancer, with almost all right-
sided adenomas of human colon and cancers possessing biofilm, whilst
left-sided cancer is rarely biofilm positive [13]. Colorectal cancer is
raising in humans younger than 50 years and is mediated by specific
dietary agents and eating regimes that influence the human gut mi-
crobiota [14]. Hence, there is a chance for prevention, diagnostics as
well as therapeutics based on the microbiota in colorectal cancer.
In normal situations, the human colon is enveloped by a mucosal
barrier that separates the microbiome from direct contact with the
colonic epithelium of the host [15]. The gap of this supportive mucus
barrier with resulting raised contact between the colonic epithelial and
microbiota has been suggested as a significant primary step in inciting
modifications in the biology of cells and inflammation that cause IBD
[16–18]. Bacterial community relationships with raised access to the
underlying epithelium are predicted to modify and thereby change
bacterial composition and activity and mostly triggering the formation
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of a biofilm [19]. A biofilm is described as associations of bacterial
societies enclosed in an exo-polymeric matrix that binds to the biotic
and abiotic surfaces [20,21]. The biofilm that invades the mucus layer
of the human colon and goes to direct connections with epithelial
mucosa shows a pathologic form [22]. Recently, the model that has
been proposed for bacteria-stimulated carcinogenesis shows how the
microbiome, bacterium to bacterium and bacterium to host interplays,
involves in colorectal cancer [10,23–25]. However, the process by
which the microbiota of human intestine interplay with themselves and
the host to trigger and the progression of colorectal cancer remains
mostly unknown. It is becoming evident that these colorectal cancer-
eliciting interplays have a role in formation and spatial compositions of
multi-bacterial societies in higher-order composition so-called biofilm
[5,10,12,13]. The possible processes comprise damages of epithelial
cells, chronic inflammation, and bacterial carcinogens, and so on
[26,27]. In this review, we will summarize and discuss the relevance of
bacterial biofilm with colorectal cancer in detail.
2. Microbiota of colon and bacterial biofilm
A microbiome is the collection of genomes from all the organisms
found in a particular environment [28]. Humans, plants, and other
animals all have microbiomes; these can be generalized to their entire
organism or broken down into specific microbiomes for different lo-
cations on them [28]. Microbiota, on the other hand, usually refers to
specific organisms that are found within a specific environment [28].
Microbiota can refer to all the organisms found in an environment,
including bacteria, viruses, and fungi [28]. This means that there are
localized differences in the microbiota of each person, depending on
where in the body the microbiota is collected from.
The human colon comprises trillions of organisms that are separated
from the human colonic epithelial cells by a dense layer of mucus [29].
This layer enhances tolerance to various foreign antigens by restricting
bacterial–epithelial impact and, therefore, mucosal inflammatory re-
actions. In contrast, bacteria can breach into the human mucus layer of
the colon with the formation of a biofilm to develop chronic mucosal
inflammation [29]. The colon microbiota is the set of organisms include
bacteria, viruses, protozoa, fungi as well as helminths, which reside in
the host colon [30]. They are becoming a crucial property of health and
disease. Now, achieving to the genomic findings of host cells and of
microbiota is more affordable. The main challenge is how to integrate
microbiota findings into precision medicine procedure for the preven-
tion, diagnosis as well as treatment of disorders like cancer [30].
Traditionally, the attempts have focused on connecting particular
bacterial factors and their respective toxins to colorectal cancer [31]. It
has led to the characterization of putative bacterial oncogenic drivers of
colorectal cancer, for instance, enterotoxigenic Bacteroides fragilis bac-
terium producing the B. fragilis toxin (BFT), Escherichia coli having the
polyketide synthase (pks) encoding the genes need to form the geno-
toxinʼs colibactin, and Fusobacterium nucleatum bacterium containing
the Fusobacterium-adhesin A (FadA) [31]. These bacteria have been
connected via epidemiological evaluations with human colorectal
cancer and have been found to trigger colon tumors in genetically
susceptible in vivo models [31]. The identification that biofilm com-
munities can harbor oncogenic risk factors offers a starting point for
various novel lines of the survey that can yield further details in terms
of the powerful tumorigenic involvement of the human microbiota to
initiate and progress of colorectal cancer.
Biofilm is a bacterial community established in the self-produced
extracellular substances that include up to 80% of bacterial associated
infections [31]. During the formation of biofilm, the bacterial cells
undergo the shifts of planktonic forms to the aggregated forms that are
buried in an extracellular polymeric substance (EPS) [32]. During these
shifts, single bacterial cells attached to a substratum. This attachment is
reversible and, then, goes irreversible once the bacteria beginning to
produce EPS including exopolysaccharide, extracellular DNA (eDNA)
and the protein [33]. In contrast to intracellular DNA, which is the DNA
located within cell membranes, eDNA represents the DNA located
outside the cells [34].
Biofilm is densely packed bacterial aggregates, embedded in a
self‐formed extracellular matrix, that are more tolerant to immune
clearance and antibacterial drugs [32,35]. The bacterial cells are
thinned inside the biofilm and produce EPS, which accounts for up to
90% of their biomass [32]. The matrix of biofilm as a fixing framework
is formed of EPS along with various carbohydrate-binding bacterial
proteins and eDNA. Nutrients are hooked by the embedded bacterial
cells in the biofilm matrix and, also, water is held [36]. The structure of
EPS is changed in response to the variations in availability of various
micro-nutrient by secretion of specific enzymes from bacterial cells,
therefore tailoring the production of bacterial biofilm to the more
certain environments [37]. The formation of biofilm is one of the
strategies that organisms apply for persistence in humans and the
progression of the disease [38].
Ecological limitations in the intestine favor the formation of biofilm
[13]. Bacterial biofilm is involved in a chronic infection that is not
simple to eliminate and appear to be a significant etiological agent in
infectious disease, particularly cystic fibrosis, and endocarditis disease
[39,40]. In terms of the later, the attachment of Streptococci to the
extracellular matrix proteins (EMPs) of human endothelial cells and
then the production of biofilm has been contributed to endocarditis
[40]. Currently, biofilm has been connected to the initiation and de-
velopment of colorectal cancer, usually in the right colon of humans
(determined as proximal host colon to the hepatic flexure) [13]. Indeed,
biofilm is much more common in tissue samples of colorectal in-
dividuals in comparison with normal controls [13].
Interplays between prokaryotes and eukaryotes are usual events.
These interplays can influence the metabolism of the encountering
members in various paths, resulting in neutral, beneficial, and/or
harmful outputs for the members [41]. For example, long neutral or
beneficial metabolic communications happen between mammalians
and their gastrointestinal tract numerous microbiome [41]. Never-
theless, these beneficial communications are less permanent and can be
disturbed by various agents including bacterial pathogens that form a
biofilm. Metabolic communication happening in eukaryotic cells sub-
sequent acute various biofilm-associated infections by pathogens are
finally often conflicting. As the host cells effort to remove the biofilm
while the pathogens attempt to benefit from host cell metabolites and
micro-nutrients and simultaneously follow their biosynthetic and bio-
energetic requirements so damaging the host cells [42,43]. Repeated
metabolic shifts can, therefore, happen on the pathogens and on the
host as well, during the biofilm-associated infections [10]. The ex-
planations of host metabolic changes via the bacterial biofilms are of
massive importance for the comprehension of biofilm pathogenesis.
An appearing probability is that the biofilm can include various
bacterial species, instead of solely a single invading bacterium provide
colonization with other pathogenic, and can cause raised inflammatory
reactions and the formation of genotoxic compounds derived from the
bacteria [44]. Accordingly, Fusobacterial spp. a dominant polybacterial
biofilm was found to abundantly exists in tumor samples from in-
dividuals with colorectal cancer and adenoma but not in paired tumor-
free samples (Fig. 1) [13]. Biofilm of driver bacteria can form new
ecological microenvironments for passenger bacteria in the develop-
ment of colorectal cancer, finally out-competing the driver bacteria
[44]. Based on the carcinoma-adenoma sequence model suggested by
Fearon et al. [45], bacterial biofilms can be regarded as the in-
dependent drivers at a primary phase of the carcinogenesis of colorectal
cancer, before the malignant conversion from host adenoma to host
carcinoma [44].
Numerous mechanisms mediating the role of bacterial biofilm in
driving the colorectal cancer process have been suggested [10,13].
These mechanisms comprise the existence of diminished rates of epi-
thelial cadherin (E-cadherin) of intestinal crypts, raised permeability of
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intestinal, the formation of polyamine metabolites and subsequently
acetylation, and prompted stimulation of Interleukin-6/Signal trans-
ducer and activator of transcription 3 (IL-6/STAT3) signaling [10,13].
To trigger colorectal cancer carcinogenesis, bacterial pathogens may
require the biofilm formation. Biofilm is not carcinogenic alone but just
in terms of unique invasive pathogens, particularly Fusobacteria spp
[13]. According to this, a biofilm has been found in the baboon, rat as
well as the non-tumorous gut of human using electron microscopy in-
vestigation [46]. Also, one work found that a biofilm can be observed in
the colon of normal murine, and a biofilm has been collected from
healthy people by colonoscopy [47]. Additionally, colonoscopic biopsy
specimen from healthy people has revealed that thin a biofilm in the
mucosa consists of relatively harmless bacteria, especially En-
terobacteriaceae, Bacteroidetes as well as Lachnospiraceae in the right
host colon, and Lachnospiraceae as well as Bacteroidetes, but notably,
no Fusobacterium, in the left host colon [13]. Most of these bacterial
associations found here in normal mucosa are commensal bacterial spp.
devoid of invasive potential [13]. Hence, the invasive capacity of bio-
film-producing bacteria could be involved in colorectal cancer patho-
genesis. To confirm this assumption, although Fusobacteria is a rela-
tively prevalent and innocuous opportunistic biofilm-producing
bacterial pathogen in the human oral cavity, in the intestine, biofilm
could also stimulate severe inflammations [48,49].
Also, co-compression of F. nucleatum cells provides colonization
with other pathogenic species in the bacterial biofilms, proposing that
the production of a biofilm can indeed offer a new ecological micro-
environment [50]. F. nucleatum cells can play as a powerful agent in the
processing of bacterial biofilm production. For instance, the in vitro
culture of a biofilm has found that this bacterium supplies a micro-
environment for attachment and growth of Tannerella forsythia cells
because F. nucleatum cells form a favorable niche for obligate anaerobe
bacteria [51]. Therefore, F. nucleatum can recruit other species into
biofilms. Campylobacter spp. like Campylobacter curvus, Campylobacter
concisus as well as Campylobacter rectus are innocuous bacterial colo-
nizers of the oral cavity of humans but are importantly mediated co-
lonic and esophageal adenocarcinoma [52]. Many oral strains of C.
concisus emerge to form zonula occludens toxin (ZOT) to stimulate
cytoskeletal changes and to disconnect tight junctions (TJs) of human
intestinal epithelial, enhancing bacterial translocation as well as in-
flammation [53]. Also, Campylobacter species are able to produce a
biofilm, for instance, Campylobacter showae co-localize with species of
Leptotrichia and Fusobacterium in colorectal tissues of human and can
raise the risk of IBD [52,54,55]. Leptotrichia has been observed to be
extremely plentiful in the human stomach with a high risk of gastric
cancer rather than humans from low-risk populations, proposed that
Leptotrichia species have the ability to stimulate intestinal cancer in
human [56]. Therefore, anaerobic bacteria like Campylobacter, Fuso-
bacterium as well as Leptotrichia emerges to be significantly mediated
colorectal cancer [54]. Also, there is a link between Streptococcus gal-
lolyticus and colorectal cancer. This bacterium has been found in
20%–50% of human colon tumor samples, while 5% of samples isolated
from normal humans showed this organism [57]. Current works have
found that Streptococci have attachment potential and the capability to
produce biofilms [40,58]. Overall, these views indicated that the bac-
terium possessing co-aggregation and invasion traits can be needed for
the production of tumor-enhancing biofilms.
3. Increased host–bacterium interplays in human colorectal
cancer by biofilm
Biofilm could involve raising the permeability of intestine and en-
hance the barrier activity losses induced by the bacteria which, in turn,
are of the most significant primary pathophysiologic changes in carci-
nogenesis of colorectal cancer in humans [59]. There are lines of the
documents show the bacterial biofilm-enhanced barrier-loss notion.
The former, pathogen invasions exist in full biofilm positive colorectal
tumors in humans, including adenomas and colorectal cancer, but this
invasiveness does not exist in biofilm negative colon tumors [13].
Latter, imaging by fluorescence in situ hybridization and scanning
electron microscope has revealed that a dense poly-bacterial biofilm
could be found in all right-sided tumors in the colon of humans, but few
bacterial biofilms have been detected in left-sided human colorectal
tumors [13]. Patients with right-sided colorectal cancer usually exist
worse clinical effects compared to individuals with left-sided colorectal
Fig. 1. The function of Fusobacterium nucleatum
biofilm on colorectal cancer. After F. nucleatum
cells detachment of biofilm, they are able to increase
the cell proliferation in host cells via distinct me-
chanisms including1) the binding of FadA adhesion
to E-cadherin which can stimulate the Wnt and β-
catenin signaling pathways, and 2) stimulation of
TLR4 and NF-κB which enable to cause the increased
formation of the oncogenic miR-21. F. nucleatum
subsequent the tumor microenvironment has devel-
oped could reach to the Gal-Gal NAC-forming tumor
cells via Fap2. F. nucleatum cells functionally change
the tumor microenvironment by the impact on the
host myeloid cells and blocking anti-tumoral im-
mune reactions of natural killers. A Normal host
epithelium; B, Hyper-proliferation of host C; Tumor
formation; LPS, lipopolysaccharide; NK, natural
killer; TLR4, Toll-like receptor4; TIGIT, T Cell
Immunoreceptor With Ig And ITIM Domains.
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cancer, which can be associated with this event [26].
Biofilm allows bacterial cells to live in next proximity to the host
intestinal epithelial barriers, a significant situation for pathogen inva-
sion and stimulation for the further inflammatory reactions [13,18,60].
Loss of intestinal barriers in humans also emerges to aggravate bacterial
dysbiosis because this failure inhibited bacterial binding to human
epithelial cells. The enhanced entry of bacterial components into host
epithelial cells can subsequently be involved in the formation of a
tumor-enhancing environment, like activating T helper 17 (Th17) im-
mune reactions and favoring the initiation of colorectal cancer [13,60].
4. Biofilm and enhanced genotoxicity in human colorectal cancer
Of the probable process by which bacterial biofilm could enhance
oncological disorders, genotoxic stress outcomes from bacterial toxins
have shown the most document connections in comparison to trans-
formation alone. For example, numerous bacteria generate different
toxins, of which Cytolethal Distending Toxin (CDT) and BFT involve in
genotoxicity and the initiation of colorectal cancer [61–65]. BFT mo-
lecules (formed by Enterotoxigenic B. fragilis) are the genotoxins that
indirectly enhance the damage of DNA [63,66]. For instance, the BFTs
in T84 and HT29/C1 colonic epithelial cells, in vitro, have been found to
cause up-regulation of spermine oxidase molecules to trigger the for-
mation of reactive oxygen species (ROS) [66]. It has been proposed that
raised reactive oxygen species formation stimulates the Nucleotide
oligomerization domain (NOD)-like receptor containing pyrin domain 3
(NLRP3) inflammasomes, a crucial activator of innate immune reac-
tions that can more trigger the damage of DNA [67].
It has been suggested that BFT cleaves the E-cadherin (an inter-
cellular adhesion molecule) of the colonic epithelial cell lines (for ex-
ample, C1/HT29, Human colonic epithelial cells), so including in-
testinal barrier activity [68,69]. The intestinal barrier deterioration can
cause raised leakage of bacterial components that can involve in colonic
adenoma (pre-malignant lesions) [60]. Subsequent, as found in Mouse
Model of Colonic Adenoma-Carcinoma Progression Based on Somatic
Apc Inactivation (CPC-APC) murine in vivo, this can cause the Inter-
leukin-23 (IL-23) and Interleukin-17 (IL-17)-contributed inflammatory
reactions, resulting in damage of DNA in cells, and finally stimulate
tumor production [60]. Especially, biofilms of B. fragilis are found to be
the key characteristics of the IBD, of which the tumor-enhancing im-
pacts of persistent intestinal inflammation of humans have now been
detected and are best-defined [12]. Actually, over 60% of the biofilm
mass collected from IBD patients has been ascribed to the Bacteroides
spp [12]. Additionally, the production rate of biofilm associations, in
vitro, found from IBD patients is significantly further than of samples
taken from humans either with no inflammation or self-limiting colitis
[12]. It is thus well-founded to suggest that a biofilm of B. fragilis is
potent to enhance intestinal inflammation and colorectal cancer. It
seems that multi-bacterial biofilms can theoretically change the in-
testinal tumor niches in many routs (like genotoxicity), and boost the
expansion of human colon cancer.
5. Impacts of biofilm on metabolism in colorectal cancer
Metabolic interactions of bacteria and hosts can indirectly or di-
rectly provoke the progression of colorectal cancer stimulated by bac-
teria. Increasing documents have linked the microbiota of intestine to
the control of many metabolic routs of exogenous and endogenous
products, like biosynthesis of secondary bile acids, catabolism of
polyamines. They also stimulated the carcinogens which in turn are
mediated enhanced risk for numerous cancers in humans, for example,
esophageal cancer, colorectal cancer as well as liver cancer
[10,63,70–72]. As a good instance, deoxycholic acid emerges to be the
most significant endogenous metabolite mediated colorectal cancer
carcinogenesis in Apc Min/positive murine, in vivo, as well as in colon
biopsies of human [71,73]. Deoxycholic acid molecules could act as the
naturally-occurring carcinogens that trigger oncogenic changes in the
epithelium of digestive tract in human because deoxycholic acid mo-
lecules have been found to stimulate DNA damages, oxidative stress as
well as genomic instability in biopsy of esophageal host tissues and
colonic cancer cells in epithelial human, and in vivo mouse models
[71,74]. Additionally, deoxycholic acid molecules enhance the pro-
liferation of tumor cells and suppress apoptosis by inducing Wnt sig-
naling in the murine models [73]. Because biofilms can conceivably
offer a very-efficient interface for dehydroxylation and deconjugation
of bile acids, the cell of the epithelium covered by bacterial biofilm is
exposed to very further rates of secondary bile acid molecules. In ad-
dition, such biofilms can also be a pool of nitrosamine and hydrogen
sulfide (H2S) that have been demonstrated to be carcinogenic and
genotoxic in vivo models, in colon cancer cells of human (HCT116,
HT29, and SW480) as well, by stimulating damages of DNA and in-
stability of genome [75,76]. Hence, it has proposed that bacterial me-
tabolism in biofilm is involve in the carcinogenic capability of the un-
derlying host epithelium.
By comparing biofilm and non-adherent bacteria, the higher rate of
butyrate is formed by non-adherent bacterial aggregations show that
preferable bacterial societies with the higher-order composition (bio-
film) can show the altered formation of short-chain fatty acids like
butyrate [77]. Fusobacterium-dominant biofilms can diminish the for-
mation of short-chain fatty acids and might enhance the colorectal tu-
morigenesis. Nevertheless, short-chain fatty acids derived from bacteria
like butyrate can also enhance the hyper-proliferation and sensitize
epithelial cells of the colon to transformation (in mismatch repair-de-
ficient Apc Min/positive mice model) as well [78]. Comprehension of
the action of short-chain fatty acids in maintaining host intestinal epi-
thelium or inducing colorectal cancer remains limited and modifica-
tions of these metabolites by bacterial biofilm certainly need more
evaluation.
Documents show that a biofilm may involve in humans colorectal
cancer via biosynthesis and acetylation of polyamine [10]. Multispecies
biofilms produce spermidine/spermine N 1-acetyltransferase enzyme,
which is required for acetylation of polyamine [10]. Therefore, the
significance of this view bolded that demonstrating spermidine/sper-
mine N 1-acetyltransferase in humans is not important for cancer de-
velopment. Hence the expression of bacterial spermidine/spermine N 1-
acetyltransferase may make a diversity in this regard [10]. Acetylated
polyamine molecules are significantly increased in biofilm-covered host
colon cancer. Moreover, paired healthy tissues compared to host co-
lonic tissue devoid of bacterial biofilm, show that bacterial biofilm
raises acetylation and catabolism of polyamine, then inducing un-
desirable proliferation of cells as well as the growth of cancer [63,79].
Additionally, enhanced rates of acetylated polyamine metabolite mo-
lecules, like N 1-acetylspermidine, N 1-acetylspermine, and particularly
N1, N 12-diacetylspermine, are found in human colorectal cancer in
comparison with matched non-tumor tissues from similar individuals
[10]. In agreement, in human colonic cancer tissue samples, polyamine
metabolite molecules at the mucosal margin, where the formation of
bacterial biofilms starts, have been shown to form stronger mode to the
center of the host cancer cell nest [10]. These data further showed that
bacterial biofilms can be the most significant pool of acetylated poly-
amines [10]. Moreover, targeted metabolomic evaluations found that
there are not any acetylated polyamine metabolites in bacterial biofilm-
negative healthy colonic biopsies of the human. Hence, these findings
more support the notion that the existence of polybacterial biofilm can
be putatively associated with the growth of tumors in the human colon
via a process involving raised rates of acetylated polyamine metabolites
[10,10,44].
6. Role of Interleukin 17 (IL-17) in Colorectal cancer
The actions and locations of human immune reactions in the col-
orectal cancer microenvironment are very heterogeneous and complex
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[80]. Reactions associated with Th1 toward established colorectal
cancer are involved in better effects of patients, whereas responses
associated with Th17 and formation of IL-17A resulted in worse effects
of patients [80]. Cancers that grow in the mouse models of colorectal
cancer are sometimes invasive and vary in some paths from human
colorectal tumors. Nevertheless, these mouse models have been applied
to survey the mechanisms by which IL-17A and Th17 boosting the
trigger and growth of colorectal cancer, which shows to contribute to
their direct impacts on colon epithelial. Particular parts of the colonic
microbiota can enhance the formation of IL-17A and IL17A-forming
cells, function in the colonic mucosa to boost carcinogenesis [80].
Raising the comprehension of the interplays between the mucosal
human immune reaction and the colonic microbiota, the activities of IL-
17 and Th17 in these interplays, and understanding how this me-
chanism is changed during the colon carcinogenesis, all can lead in
developing new approaches for preventing and treating human color-
ectal cancer.
Colorectal cancer is a late-stage disorder, whereas many in vivo
models that grow adenomas only representing primary disease. In pa-
tients, infiltrations of colorectal tumors by human immune cells are
involved in the progression of tumor and clinical outcomes. Evaluation
of the patient's effects is complex since they are influenced by disease
phase, treatment, and genetic and environmental agents. A landmark
investigation was done by Galon and colleagues indicated that the
intra-tumor host adaptive immune reactions influence clinical out-
comes, including decreased tumor recurrence [81]. These surveys have
found that host adaptive immune reactions can enhance the regression
of colorectal cancer [82]. Individuals with metastatic tumors with
mismatch repair deficiency and further rates of cytotoxic T lymphocytes
in the early tumor have a high level of reactions to checkpoint
blockade-based immunotherapy [83,84]. Therefore, cytotoxic lympho-
cyte cells exist in the tumor that is suppressed by the various im-
munosuppressive ligands in the microenvironment may be stimulated
by checkpoint blockade treatment to kill the host tumor cells [83,84].
Nevertheless, some individuals with metastatic colorectal cancer do not
react to the immunotherapy, even though the early colon tumors are
infiltrated by cytotoxic T lymphocytes. Other traits of the human im-
mune infiltrate, containing the quality of the adaptive anti-tumor im-
mune reactions can influence the progression of tumor and reaction to
immunotherapy.
The adaptive human immune reactions to colorectal cancer have
been well studied. The harmony between the patterns of gene expres-
sion of Th1 against Th17 cells inside tumors has been contributed to
patient effects, but data have not sometimes been consistent [85–87].
Approximately two-thirds of early sporadic colorectal cancers were
measured to have raised rate of IL-17A, whereas others have raised the
rate of Interferon-gamma (IFN-γ) or a combination of IFN-γ and IL-17
formation [85,87,88]. Polymorphisms in human genes encoding IL-17E,
IL-17A as well as IL-23 receptor, which are formed in the differentiation
of Th17 cells, have been involved in the elevated risk of colorectal
cancer and little outcomes [88,89]. These data offer documents that
show Th17 cells and IL-17A involved in the progression and develop-
ment of colorectal cancer [90]. Nevertheless, more researches are
needed to well-defined the activities of IL-17A and other cytokines that
can involve in the progression of colorectal tumors.
An in vivo model of colorectal cancer provides the document for the
communication among adaptive and innate immune reactions and the
microbiota of colon in tumorigenesis of colorectal disease [5]. It is not
obvious which parts of the human microbiota and which mucosal host
immune reactions can trigger sporadic and hereditary colorectal can-
cers. It is often mentioned that some bacteria like F. nucleatum, Strep-
tococcus gallolyticus, pks-positive E. coli, ETBF as well as Enterococcus
faecalis are involved in colorectal cancer [80]. Innate and adaptive
human immune reactions have involved in colon carcinogenesis in
murine colonized with ETBF cells, whereas myeloid populations in-
volved in colorectal tumor production in mice colonized with E. faecalis
and F. nucleatum [91,92]. Drewes and colleagues surveyed available
sequences of 16S ribosomal RNA (16SrRNA) gene via a single compu-
tational pipeline and five bacteria involved in sporadic colorectal: F.
nucleatum, B. fragilis, Gemella morbilliform, Parvimonas micra and Pep-
tostreptococcus stomatis [93]. F. nucleatum, G. morbilliform, P. stomatis as
well as P. micra are usually detected in the oral microbiota. Parts of the
human oral microbiota have increasingly been mediated to colorectal
cancer. Nevertheless, the impacts of these bacteria on tumorigenesis
and mucosal immune reactions have not been evaluated in the mouse.
Dejea and colleagues associated mucus-invasive biofilms to the sporadic
colorectal cancer and tumors in individuals with familial adenomatous
polyposis [13,94]. A polybacterial biofilm was found on sporadic host
colorectal cancer and non-tumor host colon tissues from the same in-
dividuals and had a role in carcinogenic shifts in colon epithelial cells
[13]. In individuals with familial adenomatous polyposis, a biofilm was
detected on normal mucosa and nonmalignant colon polyps; over 50%
of the bacterial population included pks positive E. coli and ETBF. Ad-
ministration of azoxymethane in a C57Bl/6 mouse and co-colonized
with pks positive E. coli and ETBF raised formation of IL-17A and in-
creased the adherence of pks positive E. coli to the colonic mucosa
mediated by ETBF was required for the development of colon tumor
[94]. The notion that bacteria-stimulated IL-17A mucosal host adaptive
immune reactions may be carcinogenic is protected by views that show
gastritis mediated by Helicobacter pylori requires IL-17A [95]. It has
been shown that segmented filamentous organism, a mouse bacterium,
stimulates the formation of IL-17 in the small intestine of a mouse. The
data led to the notion that particular bacteria are needed for stimulation
of intestinal immune reactions mediated by IL-17 [96].
Nevertheless, a survey is doing to detect bacteria that stimulate IL-
17 formation in the colon of humans beyond the primary association of
IL-17A formation with the colonization of ETBF. In addition, Atarshi
and colleagues found that reactions of Th17 in the host intestine with
bacteria require physical contact between the intestinal epithelial and
bacterial cells [97]. These data showed that responses mediated by the
mucosal Th17 cell require molecular patterns mediated to bacterial
cells and the physical vicinity of the bacterium to the host epithelial
cells.
7. Role of the iron released from the biofilm
Bacterial pathogens have earned many mechanisms to escape from
commensal-stimulated resistance and human immunity, mechanisms
which in turn provide the bacteria with impressive virulence factors
[98]. Formation and utilization of local luminal metabolites show key
regulators of pathogen-commensal pathobiont interplays and are re-
quired for the selection of niche and as well as controlling disease and
infection [99–101]. As microbiota dysbiosis is involved in shifts in the
rates of host and bacterial metabolites, these, in turn, provide promise
in our quest to find new therapeutic and biomarkers targets for dis-
orders induced by dysbiosis of the microbiota.
Some members of Proteobacteria require to properly produce or
incorporate metabolites, including those mediated by the iron-asso-
ciated pyrimidine and purine metabolism, from their environment to
efficiently persist and colonize in the intestine and/or to grow in the
bloodstream [102,103]. Iron is an element that has a significant action
in virulence and niche selection [98]. Current data show that bacterial
genes encoding for the acquisition of iron (Yersinia bactin, chu operon)
and utilization of propanediol (pdu-operon) are overproduced in Ad-
hering Invasive E. coli (AIEC) [104]. Moreover, the formation of cel-
lulose by AIEC involve in a promotion dependent on the iron of bac-
terial aggregation. It proposes that iron has indirect and direct impacts
on the formation of biofilms for some bacterial species. Proteobacteria
could thrive at the expense of other gut bacteria in an iron-rich en-
vironment. So, iron-acquisition offers a significant factor in bacterial
virulence. Further, pathogens (like those from the Enterobacteriaceae)
are known to show the increased capacity of iron uptake, but
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information on human mucosal biofilm was lacking. Current data have
now indicated that iron uptake is a critical process in conferring viru-
lence to pathobionts dispersed by biofilms of microbiota in individuals
with IBD.
8. Polybacterial biofilms as a stimulator of host pro-carcinogenic
inflammatory reactions
The involvement of inflammation induced by bacterial cells in
tumor growth is demonstrated in many documents [66,105,106]. Par-
ticularly, the IL-17/IL-23 signaling axis shows to be necessary for in-
flammation stimulated by the bacteria [60,107]. This route has been
found to enhance the accumulation of granulocyte with antibacterial
activity, but it could also cause DNA damages [25,60,106]. In addition,
granulocyte is particularly prone to form pro-inflammatory cytokines
like Interleukin-1 (IL-1), IL-6 as well as Interleukin-21 (IL-21) [25,60].
Also, there are studies that support activity for IL-17 in the expansion
and progression of human colorectal cancer [60,107,108]. Accordingly,
bacterial toxins like BFT, selectively enhance proinflammatory reac-
tions dependent on IL-17/IL-23-, inducing colitis disorder in the mouse
[23,24]. For instance, blockade of IL-23 and IL-17 receptors by blocking
antibodies, suppress the colitis induced by ETBF in the Apc Min/posi-
tive murine, and only STAT3 molecules are stimulated subsequent co-
lonization of ETBF [24]. In another case, depleting the intestinal bac-
terial flora in CPC-APC murine by three weeks of cocktail therapy with
broad-spectrum drugs diminished the expression of IL-17A mRNA and
reduced the activation of STAT3 in colonic tumor cells [60]. In addi-
tion, three months of drug therapy markedly decreased the size of colon
tumors in CPC-APC mice in comparison with IL-23R-deficient CPC-APC
murine, further showed that tumor-eliciting gut bacteria can enhance
the pro-oncogenic signaling dependent to IL-23 [60]. Current works
have found a significant positive connection between the increase of
intra-tumor Fusobacterium cells and the rates of various inflammatory
cytokines like IL-6 and TNF in human colorectal. Although no such a
correlation was observed in the colonic mucosa of controls, it suggested
that carcinogenesis induced by Fusobacteria can be involved in the
capability of bacterial biofilm to trigger mucosal inflammation
[109,110]. As a result, the stimulation of the immune reactions medi-
ated by IL-17/IL-23 in the intestinal epithelium can be associated with
the putative pro-oncogenic capability of bacterial biofilm. Increasing
documents also proposed the notion that mucosal biofilm prompts the
pro-oncogenic capability of bacterial dysbiosis by eliciting in-
flammatory reactions [12,13,111]. For example, the rates of mucosa-
adherent pathogens, i.e., biofilm production, were shown to be sig-
nificantly superior in biopsies from individuals with Crohn's disorder in
comparison with non-inflammatory controls, like individuals with IBD
and healthy individuals. Usually, all of the microbiota found in the host
intestinal tract of IBD patients were bonded to the epithelium [12].
Microbiota of the human intestine is controlled by interplays between
host immunity and bacterial activities, and they contributed to highly
structured spatial compositions of bacteria linked to the specific im-
mune reactions [12,13,111]. For example, highly-virulent Enterococcus
(HVE) that colonize the human rectum and colon, produce a bacterial
biofilm that supports organisms from reactive oxygen and enhances
detoxification of hydrogen peroxide activity in IBD individuals [112].
Contrariwise, biofilms also increase the specific immune reactions that
in turn can induce the development of cancer. As previously noted,
biofilms can directly cause the stimulation of IL-6/STAT3 proin-
flammatory signaling in epithelial cells of the human intestine (a well-
defined tumor-enhancing route). According to this, a current work
found that phosphorylation rates of STAT3 and IL-6 were markedly
increased in a non-tumor biopsy specimen from individuals with bac-
terial biofilm-positive colorectal cancer cells in comparison with normal
mucosal cells from bacterial biofilm-negative colorectal cancer patients
(Fig. 2) [13]. Additionally, IL-6 molecules were shown to be further
formed in biofilm-covered human intestinal mucosa with STAT3
stimulation, even in healthy controls, showed that bacterial biofilm
alone can enhance IL-6/STAT3 inflammatory signaling [13].
Other cases involved in the action of inflammation are amyloid fi-
bril molecules. The concept that inflammation is contributed to amyloid
pathogenesis was first noted in research on serum amyloid A [113,114].
Today, it is defined that this particular amyloidogenic expression is
modulated by the inflammatory cytokine, IL-6, which results in en-
hanced rates of serum amyloid A [115]. These amyloid compositions
constitute an important and common ingredient of mucosal bacterial
biofilm and are formed by dominant intestinal bacteria belonging to the
Bacteroidetes, Firmicutes as well as Proteobacteria [116–118]. Amyloid
fibril molecules like curli could stimulate the signaling of the Toll-like
receptor (TLR) in host immune cells [117,118]. Curli molecules, the
powerful Toll-like receptor 1(TLR1)/Toll-like receptor 2(TLR2) ligand,
have been found to stimulate a host response mediated to TLR2 in
murine colitis, involving in inflammatory reactions contributed to IL-
17A/Interleukin-22 (IL-22) [117–119]. In another study, by incubating
naïve CD4+T cells of the mouse with supernatant of dendritic cells
derived from bone marrow pretreated with curli molecules in vitro, the
formation of IL-17A and IL-22 could stimulate the differentiation of
naïve CD4+T lymphocytes into Th17 lymphocytes [118]. Overall, it is
thus reasonable to propose that signaling dependent on pro-oncogenic
Th17 can be enhanced by biofilm, cause the intestinal inflammation
that, when is intense, can constitute a route by which a could be biofilm
involve in colonic neoplasia in human.
9. Conclusion
Human intestinal bacterial biofilms and their compositions emerge
to play a crucial activity in sustaining and triggering colorectal pro-
gression. The molecular process in the interplay between carcinogenic
factors formed by bacteria and biofilm and host reactions in the in-
itiation and progression of colorectal cancer is now emerging. However,
it is evident that more studies will need to offer mechanistic details into
their precise contribution to the process of human cancer. The relative
credit of this phenomenon remains unknown, but with the appearance
of screening programs for colorectal cancer, and the mediated possi-
bilities for prospective works, fast progress in this regard seems likely.
When considering the distinct properties of the spatial composition of
microbiota in the distal and proximal colon tissues in humans (com-
prising normal and cancer tissues), significant questions must be in-
creased on whether the invasive formation of bacterial biofilm pre-
ferentially exists in right colon cancer of human. In line with the
unfavorable prognosis of human right-sided colorectal cancer, it has
postulated that bacterial biofilm-positive colorectal tumors can cause
worse clinical results associated with the bacterial biofilm-negative
tumors given that bacterial biofilm aggregations can cause further
Fig. 2. The mixed biofilm in the inner colonic mucus of the host. Biofilm
leads to raised gut permeability, redistribution of E-cadherin in host colonic
cells as well as the loss of activity of intestinal barrier, subsequent, increasing
intestinal dysbiosis. Host dysbiosis can favor raised growth of other opportu-
nistic organisms. The pro-oncogenic activity of the bacterial biofilm, along with
changes of polyamine metabolic and inflammation-mediated with Th17 causes
the proliferation of host cells and aberrant tumor growth.
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serious injuries and intestinal inflammation of epithelial tissue.
Additionally, current emerging documents support this notion; acety-
lated spermine could be significantly decreased in resected tumor tis-
sues from colorectal patients administering antibacterial drugs before
their surgery in comparison with untreated colonic bacterial biofilm-
covered cancer tissue specimens. It is, therefore, assumed that the in-
itiation and progression of colorectal cancer arise as a result of the pro-
oncogenic properties of bacterial biofilm of invasive bacterial patho-
gens. Preventive approaches aimed at the primary detection and sup-
pression of such bacterial biofilm deposition can prove to be profitable
for individuals with the risk of colorectal cancer. Moreover, specific
drugs targeting biofilms can be used among numerous potential ther-
apeutic protocols. Nevertheless, such approaches must be evaluated
cautiously when attempting to target cancer tissues because they
change the intestinal milieu of humans and its microbiota can cause
deleterious consequences and metabolic imbalances for the host.
Hence, there is a crucial need for models that more closely reflect the in
vivo infection conditions. Indeed, the profound comprehension of the
metabolic host cell reactions in colorectal cancer can provide novel
interesting concepts for anti-cancer treatments.
In summary, these data suggest bacterial biofilm is an important
factor contributing to colorectal cancer development. We anticipate
that evaluating bacterial biofilms as well as the type of inflammatory
reactions will provide a clearer picture of how bacteria contribute to the
initiation and progression of colorectal cancer. Identifying candidate
pro-carcinogenic bacterial species from human colon mucosal biofilms
can enable earlier screening to predict patients at risk of developing
colorectal cancer and allow the application of interventions to disrupt
the progression of colon carcinogenesis.
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